Immunomedics awarded F-18 protein labeling patent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Immunomedics, a biopharmaceutical developer of monoclonal antibodies to treat cancer and other diseases, announced that it has received U.S. patent 7,563,433--covering methods and compositions for fluorine-18 (F-18) labeling of proteins, peptides and other molecules.

The patent covers a method for attaching F-18 to peptides via a conjugate with aluminum or other metals, published by the company in the June issue of the Journal of Nuclear Medicine.

The new patent provides coverage until 2027.